Epigenomics（ECX）株式概要エピゲノミクスAGは重要な事業を行っていない。 詳細ECX ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6報酬過去5年間の収益は年間25.8%増加しました。 リスク分析キャッシュランウェイが1年未満である 収益が 100 万ドル未満 ( €24K )意味のある時価総額がありません ( €763K )German市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見るECX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.8762.0k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-17m6m2016201920222025202620282031Revenue €421.7Earnings €76.6AdvancedSet Fair ValueView all narrativesEpigenomics AG 競合他社bioXXmedSymbol: DB:T5OMarket cap: €222.9kDarwinSymbol: MUN:7V0Market cap: €68.4mHeidelberg PharmaSymbol: XTRA:HPHAMarket cap: €130.5mGenetic AnalysisSymbol: DB:8V8Market cap: €42.7m価格と性能株価の高値、安値、推移の概要Epigenomics過去の株価現在の株価€0.8752週高値€1.5952週安値€0.50ベータ0.981ヶ月の変化-6.95%3ヶ月変化-17.14%1年変化-11.41%3年間の変化-71.71%5年間の変化-97.52%IPOからの変化-99.86%最新ニュースお知らせ • Apr 21Epigenomics AG, Annual General Meeting, May 27, 2026Epigenomics AG, Annual General Meeting, May 27, 2026, at 09:00 W. Europe Standard Time.お知らせ • Apr 03Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026お知らせ • Jul 17Epigenomics AG, Annual General Meeting, Aug 27, 2025Epigenomics AG, Annual General Meeting, Aug 27, 2025, at 10:30 W. Europe Standard Time.New Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.7m free cash flow). Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$365k). Market cap is less than US$10m (€1.43m market cap, or US$1.54m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€500k net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).New Risk • Mar 24New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€8.0m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$367k). Market cap is less than US$10m (€1.57m market cap, or US$1.69m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€5.7m). Currently unprofitable and not forecast to become profitable over next 2 years (€600k net loss in 2 years). Shareholders have been diluted in the past year (6.3% increase in shares outstanding).New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (€447k revenue, or US$484k). Market cap is less than US$10m (€1.41m market cap, or US$1.52m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€14m). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€595k net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (4.2% increase in shares outstanding).最新情報をもっと見るRecent updatesお知らせ • Apr 21Epigenomics AG, Annual General Meeting, May 27, 2026Epigenomics AG, Annual General Meeting, May 27, 2026, at 09:00 W. Europe Standard Time.お知らせ • Apr 03Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026お知らせ • Jul 17Epigenomics AG, Annual General Meeting, Aug 27, 2025Epigenomics AG, Annual General Meeting, Aug 27, 2025, at 10:30 W. Europe Standard Time.New Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.7m free cash flow). Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$365k). Market cap is less than US$10m (€1.43m market cap, or US$1.54m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€500k net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).New Risk • Mar 24New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€8.0m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$367k). Market cap is less than US$10m (€1.57m market cap, or US$1.69m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€5.7m). Currently unprofitable and not forecast to become profitable over next 2 years (€600k net loss in 2 years). Shareholders have been diluted in the past year (6.3% increase in shares outstanding).New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (€447k revenue, or US$484k). Market cap is less than US$10m (€1.41m market cap, or US$1.52m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€14m). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€595k net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (4.2% increase in shares outstanding).お知らせ • Nov 29+ 2 more updatesEpigenomics AG, Annual General Meeting, May 29, 2024Epigenomics AG, Annual General Meeting, May 29, 2024.お知らせ • Oct 12New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG for $9.8 million on July 24, 2023. Under the terms of consideration, As consideration for the sale, Epigenomics AG will receive a purchase price of up to USD 12.05 million, which can be broken down as follows: Cash payments of USD 1.8 million: USD 0.5 million on the closing date, USD 1.0 million on December 1, 2023 and USD 0.3 million on June 30, 2024. Further cash payments of up to USD 8.0 million contingent on the achievement of certain milestones related to Epi proColon and foremost Epi proColon “Next-Gen”. An interest in the acquirer of 3.0%, valued at least at USD 2.25 million. In addition, the Company will receive royalty or earn-out payments, in the form of royalties linked to the commercialization of the “Next-Gen”-Test. These payments extend probably until October 2043, the year in which patent protection for the product is expected to expire. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property along with all patents as well as the entire biobank, and thus all of its assets within the meaning of Section 179a of the German Stock Corporation Act (AktG), to the acquirer. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer. The agreement is subject to certain closing conditions, including the approval at the Company’s Extraordinary General Meeting. The sale of the assets to New Day Diagnostics is expected to enable the commercialization of Epi proColon “Next-Gen” and secure future cash flows for Epigenomics AG. As of September 14, 2023, Extraordinary General Meeting of Epigenomics approved the transaction. The closing of the agreement remains subject to customary closing conditions, and both parties are diligently working towards its completion. TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors. New Day Diagnostics, LLC completed the acquisition of Substantially all of Assets of Epigenomics AG on October 10, 2023.Reported Earnings • Aug 13Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)Second quarter 2023 results: €0.62 loss per share (further deteriorated from €0.32 loss in 2Q 2022). Revenue: €70.0k (down 44% from 2Q 2022). Net loss: €2.63m (loss widened 102% from 2Q 2022). Revenue is forecast to grow 76% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.Buying Opportunity • Aug 03Now 29% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.お知らせ • Jul 26New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG on July 24, 2023. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors.Buying Opportunity • Jul 19Now 24% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €0.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.お知らせ • Jun 13Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5mEpigenomics AG (XTRA:ECX1) shares more than doubled in value on June 12, 2023 after it said it is holding talks with an unidentified U.S. company to sell nearly all of its assets for around $11.5 million. The German medical diagnostic company said the potential deal, which is unbinding and therefore could still fail, relates to the patents and other rights of its blood tests to screen for colon cancer and all blood samples owned by Epigenomics. Current negotiations place the deal closing in December, Epigenomics said. The unidentified acquirer would also have to pay royalties and other costs associated with the potential commercialization of a diagnostic test in development.Price Target Changed • Jun 02Price target increased by 9.1% to €6.00Up from €5.50, the current price target is provided by 1 analyst. New target price is 926% above last closing price of €0.58. Stock is down 68% over the past year. The company is forecast to post a net loss per share of €1.63 next year compared to a net loss per share of €2.96 last year.Reported Earnings • Jun 01First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)First quarter 2023 results: €1.31 loss per share (further deteriorated from €0.67 loss in 1Q 2022). Net loss: €5.59m (loss widened 110% from 1Q 2022). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.お知らせ • May 20Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023Epigenomics AG announced that Member of the Executive Board, President, and Chief Scientific Officer Dr. Andrew Lukowiak, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective May 31, 2023. Between now and the resignation date Dr. Lukowiak will continue to support the Company’s restructuring efforts in coordination with the Supervisory Board. The Company continues to be committed to maximizing the value of its technology through corporate partnering, licensing and/or asset sales. Dr. Lukowiak has been a Member of the Executive Board, President, and CSO of Epigenomics AG since December 2021. His broad contributions across the organization have been instrumental in furthering the Company’s colorectal cancer diagnostics’ program, including his systematic optimization of R&D structure and processes, as well as his execution of complementary partnerships. However, in recent months, in the current capital market environment, the Company has been unable to raise additional capital to secure funding for the FDA pivotal study of the "Next-Gen" test. In response, the restructuring of the Company was initiated on February 15, 2023 to minimize costs. Against this backdrop, the resignation of Dr. Andrew Lukowiak now also takes place.Reported Earnings • May 01Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)Full year 2022 results: €2.96 loss per share (further deteriorated from €0.87 loss in FY 2021). Net loss: €12.0m (loss widened 395% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.Breakeven Date Change • Dec 22No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €25.8m in 2024.Breakeven Date Change • Nov 16No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: €0.10 loss per share. Net loss: €1.56m (down 155% from profit in 3Q 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.お知らせ • Nov 09+ 2 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023Reported Earnings • Aug 15Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €126.0k (up 7.7% from 2Q 2021). Net loss: €1.30m (loss narrowed 44% from 2Q 2021). Over the next year, revenue is expected to shrink by 91% compared to a 12% growth forecast for the Biotechs industry in Germany.Price Target Changed • Jun 01Price target increased to €1.07Up from €0.95, the current price target is an average from 2 analysts. New target price is 117% above last closing price of €0.49. Stock is down 72% over the past year. The company is forecast to post a net loss per share of €0.99 next year compared to a net loss per share of €0.22 last year.Reported Earnings • May 14First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: €0.17 loss per share. Revenue: €115.0k (up 8.5% from 1Q 2021). Net loss: €2.66m (loss widened 121% from 1Q 2021). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 91% compared to a 36% growth forecast for the industry in Germany.Price Target Changed • Apr 27Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 106% above last closing price of €0.46. Stock is down 63% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.Breakeven Date Change • Apr 06No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.Price Target Changed • Mar 28Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 77% above last closing price of €0.54. Stock is down 79% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.Price Target Changed • Jan 23Price target decreased to €1.14Down from €1.39, the current price target is an average from 2 analysts. New target price is 122% above last closing price of €0.51. Stock is down 80% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €2.02 last year.Is New 90 Day High Low • Mar 07New 90-day low: €2.19The company is down 39% from its price of €3.57 on 07 December 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.33 per share.Is New 90 Day High Low • Jan 31New 90-day low: €2.27The company is down 53% from its price of €4.80 on 02 November 2020. The German market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.76 per share.Price Target Changed • Dec 16Price target lowered to €23.73Down from €32.80, the current price target is an average from 3 analysts. The new target price is 638% above the current share price of €3.22. As of last close, the stock is down 71% over the past year.株主還元ECXDE BiotechsDE 市場7D-6.5%1.8%2.4%1Y-11.4%-12.5%1.2%株主還元を見る業界別リターン: ECX過去 1 年間で-12.5 % のリターンをもたらしたGerman Biotechs業界と一致しました。リターン対市場: ECXは、過去 1 年間で1.2 % のリターンを上げたGerman市場を下回りました。価格変動Is ECX's price volatile compared to industry and market?ECX volatilityECX Average Weekly Movement19.0%Biotechs Industry Average Movement8.5%Market Average Movement6.1%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.7%安定した株価: ECXの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ECXの weekly volatility ( 19% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19983Noel Dohenywww.epigenomics.comエピゲノミクスAGは重要な事業を行っていない。以前は癌の早期発見のためのリキッドバイオプシーに携わっていた。同社は1998年に設立され、ドイツのハイデルベルクに本社を置いている。もっと見るEpigenomics AG 基礎のまとめEpigenomics の収益と売上を時価総額と比較するとどうか。ECX 基礎統計学時価総額€762.97k収益（TTM）-€314.00k売上高(TTM)€24.00k31.8xP/Sレシオ-2.4xPER（株価収益率ECX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ECX 損益計算書（TTM）収益€24.00k売上原価€0売上総利益€24.00kその他の費用€338.00k収益-€314.00k直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.36グロス・マージン100.00%純利益率-1,308.33%有利子負債／自己資本比率569,050.0%ECX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 13:16終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Epigenomics AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Hans Bjorn BostromEdison Investment ResearchSimon ScholesFirst Berlin Equity Research GmbHBryan BrokmeierMaxim Group2 その他のアナリストを表示
お知らせ • Apr 21Epigenomics AG, Annual General Meeting, May 27, 2026Epigenomics AG, Annual General Meeting, May 27, 2026, at 09:00 W. Europe Standard Time.
お知らせ • Apr 03Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026
お知らせ • Jul 17Epigenomics AG, Annual General Meeting, Aug 27, 2025Epigenomics AG, Annual General Meeting, Aug 27, 2025, at 10:30 W. Europe Standard Time.
New Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.7m free cash flow). Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$365k). Market cap is less than US$10m (€1.43m market cap, or US$1.54m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€500k net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).
New Risk • Mar 24New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€8.0m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$367k). Market cap is less than US$10m (€1.57m market cap, or US$1.69m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€5.7m). Currently unprofitable and not forecast to become profitable over next 2 years (€600k net loss in 2 years). Shareholders have been diluted in the past year (6.3% increase in shares outstanding).
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (€447k revenue, or US$484k). Market cap is less than US$10m (€1.41m market cap, or US$1.52m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€14m). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€595k net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (4.2% increase in shares outstanding).
お知らせ • Apr 21Epigenomics AG, Annual General Meeting, May 27, 2026Epigenomics AG, Annual General Meeting, May 27, 2026, at 09:00 W. Europe Standard Time.
お知らせ • Apr 03Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026
お知らせ • Jul 17Epigenomics AG, Annual General Meeting, Aug 27, 2025Epigenomics AG, Annual General Meeting, Aug 27, 2025, at 10:30 W. Europe Standard Time.
New Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.7m free cash flow). Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$365k). Market cap is less than US$10m (€1.43m market cap, or US$1.54m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€500k net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).
New Risk • Mar 24New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€8.0m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$367k). Market cap is less than US$10m (€1.57m market cap, or US$1.69m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€5.7m). Currently unprofitable and not forecast to become profitable over next 2 years (€600k net loss in 2 years). Shareholders have been diluted in the past year (6.3% increase in shares outstanding).
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (€447k revenue, or US$484k). Market cap is less than US$10m (€1.41m market cap, or US$1.52m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€14m). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€595k net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (4.2% increase in shares outstanding).
お知らせ • Nov 29+ 2 more updatesEpigenomics AG, Annual General Meeting, May 29, 2024Epigenomics AG, Annual General Meeting, May 29, 2024.
お知らせ • Oct 12New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG for $9.8 million on July 24, 2023. Under the terms of consideration, As consideration for the sale, Epigenomics AG will receive a purchase price of up to USD 12.05 million, which can be broken down as follows: Cash payments of USD 1.8 million: USD 0.5 million on the closing date, USD 1.0 million on December 1, 2023 and USD 0.3 million on June 30, 2024. Further cash payments of up to USD 8.0 million contingent on the achievement of certain milestones related to Epi proColon and foremost Epi proColon “Next-Gen”. An interest in the acquirer of 3.0%, valued at least at USD 2.25 million. In addition, the Company will receive royalty or earn-out payments, in the form of royalties linked to the commercialization of the “Next-Gen”-Test. These payments extend probably until October 2043, the year in which patent protection for the product is expected to expire. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property along with all patents as well as the entire biobank, and thus all of its assets within the meaning of Section 179a of the German Stock Corporation Act (AktG), to the acquirer. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer. The agreement is subject to certain closing conditions, including the approval at the Company’s Extraordinary General Meeting. The sale of the assets to New Day Diagnostics is expected to enable the commercialization of Epi proColon “Next-Gen” and secure future cash flows for Epigenomics AG. As of September 14, 2023, Extraordinary General Meeting of Epigenomics approved the transaction. The closing of the agreement remains subject to customary closing conditions, and both parties are diligently working towards its completion. TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors. New Day Diagnostics, LLC completed the acquisition of Substantially all of Assets of Epigenomics AG on October 10, 2023.
Reported Earnings • Aug 13Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)Second quarter 2023 results: €0.62 loss per share (further deteriorated from €0.32 loss in 2Q 2022). Revenue: €70.0k (down 44% from 2Q 2022). Net loss: €2.63m (loss widened 102% from 2Q 2022). Revenue is forecast to grow 76% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
Buying Opportunity • Aug 03Now 29% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.
お知らせ • Jul 26New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG on July 24, 2023. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors.
Buying Opportunity • Jul 19Now 24% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €0.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.
お知らせ • Jun 13Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5mEpigenomics AG (XTRA:ECX1) shares more than doubled in value on June 12, 2023 after it said it is holding talks with an unidentified U.S. company to sell nearly all of its assets for around $11.5 million. The German medical diagnostic company said the potential deal, which is unbinding and therefore could still fail, relates to the patents and other rights of its blood tests to screen for colon cancer and all blood samples owned by Epigenomics. Current negotiations place the deal closing in December, Epigenomics said. The unidentified acquirer would also have to pay royalties and other costs associated with the potential commercialization of a diagnostic test in development.
Price Target Changed • Jun 02Price target increased by 9.1% to €6.00Up from €5.50, the current price target is provided by 1 analyst. New target price is 926% above last closing price of €0.58. Stock is down 68% over the past year. The company is forecast to post a net loss per share of €1.63 next year compared to a net loss per share of €2.96 last year.
Reported Earnings • Jun 01First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)First quarter 2023 results: €1.31 loss per share (further deteriorated from €0.67 loss in 1Q 2022). Net loss: €5.59m (loss widened 110% from 1Q 2022). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
お知らせ • May 20Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023Epigenomics AG announced that Member of the Executive Board, President, and Chief Scientific Officer Dr. Andrew Lukowiak, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective May 31, 2023. Between now and the resignation date Dr. Lukowiak will continue to support the Company’s restructuring efforts in coordination with the Supervisory Board. The Company continues to be committed to maximizing the value of its technology through corporate partnering, licensing and/or asset sales. Dr. Lukowiak has been a Member of the Executive Board, President, and CSO of Epigenomics AG since December 2021. His broad contributions across the organization have been instrumental in furthering the Company’s colorectal cancer diagnostics’ program, including his systematic optimization of R&D structure and processes, as well as his execution of complementary partnerships. However, in recent months, in the current capital market environment, the Company has been unable to raise additional capital to secure funding for the FDA pivotal study of the "Next-Gen" test. In response, the restructuring of the Company was initiated on February 15, 2023 to minimize costs. Against this backdrop, the resignation of Dr. Andrew Lukowiak now also takes place.
Reported Earnings • May 01Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)Full year 2022 results: €2.96 loss per share (further deteriorated from €0.87 loss in FY 2021). Net loss: €12.0m (loss widened 395% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.
Breakeven Date Change • Dec 22No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €25.8m in 2024.
Breakeven Date Change • Nov 16No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.
Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: €0.10 loss per share. Net loss: €1.56m (down 155% from profit in 3Q 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.
お知らせ • Nov 09+ 2 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023
Reported Earnings • Aug 15Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €126.0k (up 7.7% from 2Q 2021). Net loss: €1.30m (loss narrowed 44% from 2Q 2021). Over the next year, revenue is expected to shrink by 91% compared to a 12% growth forecast for the Biotechs industry in Germany.
Price Target Changed • Jun 01Price target increased to €1.07Up from €0.95, the current price target is an average from 2 analysts. New target price is 117% above last closing price of €0.49. Stock is down 72% over the past year. The company is forecast to post a net loss per share of €0.99 next year compared to a net loss per share of €0.22 last year.
Reported Earnings • May 14First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: €0.17 loss per share. Revenue: €115.0k (up 8.5% from 1Q 2021). Net loss: €2.66m (loss widened 121% from 1Q 2021). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 91% compared to a 36% growth forecast for the industry in Germany.
Price Target Changed • Apr 27Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 106% above last closing price of €0.46. Stock is down 63% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.
Breakeven Date Change • Apr 06No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.
Price Target Changed • Mar 28Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 77% above last closing price of €0.54. Stock is down 79% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.
Price Target Changed • Jan 23Price target decreased to €1.14Down from €1.39, the current price target is an average from 2 analysts. New target price is 122% above last closing price of €0.51. Stock is down 80% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €2.02 last year.
Is New 90 Day High Low • Mar 07New 90-day low: €2.19The company is down 39% from its price of €3.57 on 07 December 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.33 per share.
Is New 90 Day High Low • Jan 31New 90-day low: €2.27The company is down 53% from its price of €4.80 on 02 November 2020. The German market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.76 per share.
Price Target Changed • Dec 16Price target lowered to €23.73Down from €32.80, the current price target is an average from 3 analysts. The new target price is 638% above the current share price of €3.22. As of last close, the stock is down 71% over the past year.
